Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Declines By 49.3%

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totaling 1,385 shares, a decline of 49.3% from the July 15th total of 2,733 shares. Based on an average trading volume of 790 shares, the short-interest ratio is presently 1.8 days. Approximately 0.0% of the company’s shares are short sold.

Institutional Investors Weigh In On Molecular Partners

A hedge fund recently raised its position in Molecular Partners stock. SmartHarvest Portfolios LLC increased its stake in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) by 26.3% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 15,543 shares of the company’s stock after acquiring an additional 3,232 shares during the period. SmartHarvest Portfolios LLC’s holdings in Molecular Partners were worth $62,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 26.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on MOLN. HC Wainwright restated a “buy” rating on shares of Molecular Partners in a report on Monday, July 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a research report on Wednesday, July 8th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $8.38.

Molecular Partners Price Performance

NASDAQ MOLN traded up $0.07 during trading hours on Monday, hitting $4.28. The company had a trading volume of 1,545 shares, compared to its average volume of 4,986. Molecular Partners has a fifty-two week low of $3.47 and a fifty-two week high of $5.36. The company has a market capitalization of $172.62 million, a price-to-earnings ratio of -2.20 and a beta of 1.08. The firm’s 50 day moving average is $3.99 and its 200 day moving average is $4.23.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.